Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination

Vaccine

Volumn 27, Issue 36, 2009, Pages 4938-4946

  Zhang, Wenjuan ^a   Du, Xiaogang ^a   Zhao, Gang ^a   Jin, Huali ^a   Kang, Youmin ^a   Xiao, Chong ^a   Liu, Mingyu ^a   Wang, Bin ^a  

^a Department of Microbiology and Immunology   (China)

Author keywords

Cellular responses; HBV vaccine; Levamisole; MyD88; TLR7 8

Indexed keywords

ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; BETA INTERFERON; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LEVAMISOLE; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B SURFACE ANTIGEN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS B; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; UPREGULATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; INTERFERON REGULATORY FACTOR-7; INTERFERON-ALPHA; INTERFERON-GAMMA; LEVAMISOLE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; TH1 CELLS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VACCINES, SUBUNIT;

EID: 67650432475     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.012     Document Type: Article

References (20)

1. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
2. Park H.S., Kim Y.J., Bae Y.K., Lee N.H., Lee Y.J., Hah J.O., et al. Differential expression patterns of IRF3 and IRF7 in pediatric lymphoid disorders. Int J Biol Markers 22 January-March (1) (2007) 34-38
3. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 January Suppl. 1 (1995) S47-S49
4. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 April (4) (2008) 869-882
5. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 February (2) (2002) 196-200
6. Gupta R.K., and Siber G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13 October (14) (1995) 1263-1276
7. Jin H., Li Y., Ma Z., Zhang F., Xie Q., Gu D., et al. Effect of chemical adjuvants on DNA vaccination. Vaccine 22 July (21-22) (2004) 2925-2935
8. Gu Q.L., Huang X., Ren W.H., Shen L., Liu B.Y., and Chen S.Y. Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency. World J Gastroenterol 13 November (44) (2007) 5911-5917
9. Schon M.P., and Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27 January (2) (2008) 190-199
10. Harrison L.I., Astry C., Kumar S., and Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 47 August (8) (2007) 962-969
11. Malanchere-Bres E., Payette P.J., Mancini M., Tiollais P., Davis H.L., and Michel M.L. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol 75 July (14) (2001) 6482-6491
12. Kang Y., Jin H., Zheng G., Xie Q., Yin J., Yu Y., et al. The adjuvant effect of levamisole on killed viral vaccines. Vaccine 23 July (48-49) (2005) 5543-5550
13. Ishikawa T., Kono D., Chung J., Fowler P., Theofilopoulos A., Kakumu S., et al. Polyclonality and multispecificity of the CTL response to a single viral epitope. J Immunol 161 December (11) (1998) 5842-5850
14. Piriou L., Chilmonczyk S., Genetet N., and Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 41 December (4) (2000) 289-297
15. Schirmbeck R., Stober D., El Kholy S., Riedl P., and Reimann J. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes. J Immunol 168 June (12) (2002) 6253-6262
16. Pietras E.M., Saha S.K., and Cheng G. The interferon response to bacterial and viral infections. J Endotoxin Res 12 4 (2006) 246-250
17. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int Immunol 17 January (1) (2005) 1-14
18. Song X.T., Evel-Kabler K., Rollins L., Aldrich M., Gao F., Huang X.F., et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3 January (1) (2006) e11
19. Holcombe R.F., McLaren C.E., and Milovanovic T. Immunomodulation with low dose levamisole in patients with colonic polyps. Cancer Detect Prev 30 1 (2006) 94-98
20. Sun S., Zhang X., Tough D.F., and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188 December (12) (1998) 2335-2342